MARKETING ANALYSIS OF VACCINES USED FOR INFLUENZA IMMUNOPROPHYLAXIS IN THE REPUBLIC OF BASHKORTOSTAN
The study of cases of infectious diseases detected for the first time in the Republic of Bashkortostan (RB) revealed that in the group of infectious diseases, the nature of which is well studied, but the system of effective measures to combat them has not yet been developed, the greatest increase in morbidity in 2020 compared to 2015 was observed for influenza - by 341.16%. Therefore, the topic of marketing analysis on vaccines used in influenza immunoprophylaxis is relevant and timely. The analysis of the range of vaccines for the prevention of influenza was carried out by us according to the pharmaceutical market of the Republic of Bashkortostan, taking into account the information of the information and analytical system «State Register of Medicines» (GRLS) as of 08/23/2022 and presented by the 4th generation (generations). It was found that in the 2020/2021 epidemic season, relative to the 2015/2016 epidemic season, with a general decrease in the range of vaccines in the pharmaceutical market of the Republic of Bashkortostan, there was a 30.00% increase in the share of trivalent vaccines and 10.84% increase in the share of quadrivalent vaccines, the effectiveness of which increases the antigenic coincidence of influenza virus lines, the amount of costs prevented. Within the framework of the National Calendar of Preventive Vaccinations in the Republic of Bashkortostan, the transition to quadrivalent vaccines for immunoprophylaxis was not carried out, however, these vaccines were purchased by the population and organizations of Republic of Bashkortostan in pharmaceutical organizations for additional funds.